Medtide Inc. (HKG:3880)
Hong Kong · Delayed Price · Currency is HKD 22.26
-0.02 (-0.09%)
Apr 17, 2026, 4:08 PM HKT
Medtide Revenue
In the year 2025, Medtide had annual revenue of 570.09M CNY with 28.91% growth. Medtide had revenue of 316.32M in the half year ending December 31, 2025, with 81.90% growth.
Revenue
570.09M CNY
Revenue Growth
+28.91%
P/S Ratio
4.98
Revenue / Employee
1.01M CNY
Employees
566
Market Cap
3.16B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 570.09M | 127.86M | 28.91% |
| Dec 31, 2024 | 442.23M | 105.45M | 31.31% |
| Dec 31, 2023 | 336.77M | -14.07M | -4.01% |
| Dec 31, 2022 | 350.84M | 68.71M | 24.35% |
| Dec 31, 2021 | 282.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 1.92B |
| AIM Vaccine | 1.30B |
| Qyuns Therapeutics | 897.99M |
| BioDlink International Company | 831.99M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| Mirxes Holding Company | 166.32M |
| Antengene Corporation | 117.22M |
| Jiangsu Recbio Technology | 14.16M |